CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
The Zhitong Finance App learned that CRO concept stocks generally rose in early trading. As of press release, Pharmaceutical Biotech (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Everbright Securities said that as interest rates on US bonds fall, market risk appetite is likely to rise, which is beneficial for risk assets in innovative pharmaceuticals to enter an upward valuation channel. After entering the interest rate cut channel in the future, a favorable interest rate environment will bring improvements in financing, which will promote the rapid development of the long-term innovation industry chain.
Fu Rui pointed out that from the perspective of market accounts, Yao Ming Biotech is currently at an inflection point, and believes that its risk and reward curves tend to rise more than decline. The bank pointed out that as the US Biological Act progresses, in particular, how to handle existing contracts will become more clear. Currently, investors assume that the bill will be passed in some form; the bill should not be as severe as it seems, and they estimate that new projects from Yao Ming Biotech and even Chinese peers will come from the European Union, China, and other parts of the world rather than the US within the next 3 to 5 years.